Temozolomide in aggressive pituitary tumours and pituitary carcinomas

A McCormack - Best Practice & Research Clinical Endocrinology & …, 2022 - Elsevier
Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …
被引用次数：15 相关文章

Temozolomide in aggressive pituitary tumours and pituitary carcinomas

A McCormack - Best practice & research. Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …

Temozolomide in aggressive pituitary tumours and pituitary carcinomas.

A McCormack - Best Practice & research. Clinical Endocrinology & …, 2022 - europepmc.org
Survival for patients with aggressive pituitary tumours (APT) and pituitary carcinomas (PC)
has significantly improved following the increasing use of temozolomide (TMZ) since the first …